**Appendix Table C72. Adverse events: Comparator, embryonal tumors**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study (Investigator, country, year)** | **Record Number** | **Group (N)** | **Severity or Grade Infection** | **%** | **Severity or Grade Secondary Malignancies** | **F/U (mos) SM** | **% SM** |
| Bernstein, USA/Canada 2006 | 6290 |  | death | 5 of 110 (4.5%) | MDS | at 20 mos after dx | 1/110 1% |
| Bhatia,USA, 2007 | 43210 |  |  |  |  |  | cumulative incidence of t-MDS/AML of 11% at 5 yrs from dx |
| Kushner, USA, 1995 | 21430 | 24 |  |  | leukemia dead at 10.5 mos after HSCT in CR from ESFT |  | 4 |
| Meyers, USA, 2001 | 13670 | 9 nonHSCT |  | 11% sepsis during induction CT |  |  |  |
| Milano, Italy, 2006 | 43290 |  |  |  |  |  |  |
| Sari, Turkey, 2010 | 42790 | 36 |  |  |  |  | 0% |
| van winkle, USA, 2005 | 43550 |  |  |  |  |  |  |